Prevalence of Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma: A Comprehensive Review
Main Article Content
Abstract
Central nervous system (CNS) relapse in diffuse large B-cell lymphoma (DLBCL) is a rare but serious complication associated with poor outcomes. The prevalence of CNS relapse in DLBCL varies widely in the literature, ranging from 1% to 30%, depending on several risk factors and diagnostic methods. This article provides a comprehensive review of the current literature on the prevalence of CNS relapse in DLBCL, focusing on risk factors, diagnostic approaches, and treatment strategies. Understanding the epidemiology and clinical characteristics of CNS relapse in DLBCL is crucial for the development of effective preventive and therapeutic strategies.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. (2020). The prevention of central nervous system relapse in diffuse large b‐cell lymphoma: a british society for haematology good practice paper. british journal of haematology, 190(5), 708-714.
https://doi.org/10.1111/bjh.16866
II. (2016). Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large b-cell lymphoma patients by the spanish lymphoma group (geltamo). haematologica, 102(2),235-245. https://doi.org/10.3324/haematol.2016.149120
III. (2008). Understanding intraocular lymphomas. Clinical and experimental ophthalmology, 36(6), 564-578. https://doi.org/10.1111/j.1442-9071.2008.01843.x
IV. (2017). Central nervous system relapse of diffuse large b-cell lymphoma in the rituximab era: results of the uk ncri r-chop-14 versus 21 trial. Annals of oncology, 28(10), 2511-2516.
https://doi.org/10.1093/annonc/mdx353
V. Warley F, Cristaldo N, Colucci G, Otero V. Recaída en sistema nervioso central en linfoma difuso de células B grandes: estudio de cohorte retrospectiva [Central nervous system relapse in diffuse large B lymphoma: a retrospective cohort study]. Rev Fac Cien Med Univ Nac Cordoba. 2021 Jun 28;78(2):142-146. Spanish.
doi: 10.31053/1853.0605.v78.n2.28183.
PMID: 34181848; PMCID: PMC8741305.
VI. (2015). Treatment strategies in primary vitreoretinal lymphoma. jama ophthalmology, 133(2), 191. https://doi.org/10.1001/jamaophthalmol.2014.4755
VII. (2014). Absolute peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large b-cell lymphoma. haematologica, 100(1), 87-90.
https://doi.org/10.3324/haematol.2014.114934
VIII. (2010). most primary central nervous system diffuse large b-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases. Modern pathology, 23(2), 235-243. https://doi.org/10.1038/modpathol.2009.164
IX. (2001). Primary breast lymphoma: a report of 20 cases. british journal of haematology, 115(2), 253-256.
https://doi.org/10.1046/j.1365-2141.2001.03047.x
X. (2017). Secondary cns relapse in diffuse large b-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies. Hematology, 2017(1), 578-586.
https://doi.org/10.1182/asheducation-2017.1.578
XI. (2019). Primary testicular lymphoma: a seer analysis of 1,169 cases. Oncology letters. https://doi.org/10.3892/ol.2019.9953
XII. (2015). Primary testicular diffuse large b-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the international ptl consortium. Leukemia, 30(2), 361-372.
https://doi.org/10.1038/leu.2015.237
XIII. (2016). Diffuse large b‐cell lymphoma with testicular involvement: outcome and risk of cns relapse in the rituximab era. british journal of haematology, 176(2), 210-221.
https://doi.org/10.1111/bjh.14392
XIV. (2023). Real-world experiences of cns-directed chemotherapy followed by autologous stem cell transplantation for secondary cns involvement in relapsed or refractory diffuse large b-cell lymphoma. Frontiers in oncology, 12. https://doi.org/10.3389/fonc.2022.1071281
XV. (2015). High frequency of myd88 mutations in vitreoretinal b-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates. Blood, 126(1), 76-79.
https://doi.org/10.1182/blood-2015-01-620518
XVI. (2022). Systemic relapse in a young adult patient with primary cns diffuse large b-cell lymphoma. Case reports in hematology, 2022, 1-9.
https://doi.org/10.1155/2022/7139661
XVII. (2023). Phosphoproteome analysis of cerebrospinal fluid extracellular vesicles in primary central nervous system lymphoma. The analyst, 148(15), 3594-3602. https://doi.org/10.1039/d3an00670k
XVIII. (2021). Ineffectiveness of high‐dose methotrexate for prevention of cns relapse in diffuse large b‐cell lymphoma. american journal of hematology, 96(7), 764-771. https://doi.org/10.1002/ajh.26181
XIX. (2012). Isolated central nervous system relapses in primary mediastinal large b‐cell lymphoma after chop‐like chemotherapy with or without rituximab. Hematological oncology, 31(1), 10-17. https://doi.org/10.1002/hon.2012
XX. (2021). Prophylaxis with intrathecal or high-dose methotrexate in diffuse large b-cell lymphoma and high risk of cns relapse. Blood cancer journal, 11(6). https://doi.org/10.1038/s41408-021-00506-3
XXI. (2018). Adrenal relapse of primary central nervous system diffuse large b-cell lymphoma. Medicine, 97(38),e12482. https://doi.org/10.1097/md.0000000000012482
XXII. (2014). lmo2 and bcl6 are associated with improved survival in primary central nervous system lymphoma. british journal of haematology, 165(5), 640-648. https://doi.org/10.1111/bjh.12801
XXIII. (2022). Case report: cd19-directed car-t cell therapy combined with btk inhibitor and pd-1 antibody against secondary central nervous system lymphoma. Frontiers in immunology, 13. https://doi.org/10.3389/fimmu.2022.983934